TL;DR
Turn your wind-down time into listening time
- Thousands of audiobooks, podcasts and originals
- Listen on your phone, tablet or Echo — also offline
- Cancel anytime
A paper in The Lancet Healthy Longevity argues that sarcopenia and age-related mobility loss should be understood as problems involving the wider motor system, including nerves and the brain, as well as muscle. The authors propose changes to research and clinical assessment, but say new measures have not yet been shown to improve outcomes or reduce costs.
Researchers writing in The Lancet Healthy Longevity argue that age-related weakness and mobility loss, commonly grouped under sarcopenia, cannot be explained by muscle decline alone. Their paper proposes viewing the condition as a disorder of the aging motor system—including the brain, spinal cord and nerves—and calls for research to test whether that broader model can improve assessment and care.
The authors say diagnostic practice has already shifted toward measuring grip strength, walking speed and chair stands, rather than relying chiefly on muscle mass. Those functional measures predict outcomes such as falls and disability more effectively than muscle mass, according to the paper. But, they argue, the explanation for weakness has not kept pace: sarcopenia is still often treated as a disease of muscle, with reduced strength assumed to follow muscle wasting.
The paper says muscle loss accounts for only a modest proportion of the strength decline seen with age. People with similar muscle mass can have different levels of strength and mobility, while exercise can improve function even when measurable muscle mass does not change. The authors propose that age-related changes to movement planning, nerve signals, balance and position sense may help explain that gap. These mechanisms are presented as a case for a broader model, not as proof that existing sarcopenia diagnoses should be replaced.
The researchers outline a five-point agenda for international groups responsible for diagnostic criteria. For primary care, they suggest looking beyond whether a person can rise from a chair to how quickly they do it, and observing unsteadiness during sustained effort, hand dexterity and walking while talking. They also say clinicians should examine weakness more closely when it is asymmetric, rapid or out of proportion to muscle loss, and review medicines that may blunt motor function, including sedatives and anticholinergic drugs.
Why Function May Need a Broader Lens
The argument matters because weakness can limit everyday tasks before a major loss of independence is apparent. The authors say a muscle-only approach may miss factors affecting how effectively the nervous system recruits and controls muscle. If the proposed model is supported, assessment and research could pay more attention to movement quality and nerve function, not just muscle size or strength.
The public-health stakes are substantial in Australia, the setting highlighted in the report. Sarcopenia affects up to 29% of community-dwelling older adults, with higher rates reported in hospital and residential-care settings and among people with frailty or multiple conditions. The report cites 253,800 fall-related hospitalizations in 2024–25 and 6,722 deaths following falls in the previous year, as well as an estimated A$5.4 billion cost to the health system from fall injuries. These figures describe the scale of falls, not the number caused by sarcopenia alone.
The proposed shift could redirect some research investment from strategies focused mainly on increasing muscle mass toward interventions measured by everyday abilities, such as walking and rising from a chair. The paper does not establish that any particular new test or treatment would prevent falls or preserve independence; it argues that those questions should be tested.
Products Worth Considering
Bowflex SelectTech 840 Adjustable Kettlebell
Withings Sleep Under-Mattress Sleep Tracking Pad
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black, with 2 Brush Heads and Travel Case
As an affiliate, we earn on qualifying purchases.
How Sarcopenia Measures Have Shifted
The report says Australian primary-care clinicians have recently been given a proposed algorithm for screening, assessing and managing poor muscle health. The algorithm appeared earlier in 2026 in the Australian Journal of General Practice. The new paper in The Lancet Healthy Longevity addresses a related question: what biological systems should clinicians and researchers examine when an older person becomes weaker or slower?
Historically, sarcopenia was closely associated with loss of muscle mass. According to the authors, diagnostic emphasis has moved toward strength and physical performance because those measures better predict important outcomes. They argue that clinical definitions have changed more quickly than the underlying account of what causes functional decline.
The paper, by Lucas B. R. Orssatto and colleagues, is titled “Reframing sarcopenia as a disease of the ageing motor system” and was published in 2026. It presents a proposed framework and research agenda; it is not evidence that current clinical guidelines have already adopted that framework.
“Muscle loss explains only a modest proportion of the strength decline seen in older adults.”
— The paper’s authors
Tests and Benefits Still Need Proof
The paper proposes a broader view of sarcopenia, but it does not show that its suggested observations—such as chair-rise speed, dual-task walking or hand dexterity—outperform existing screening methods. The authors explicitly say that the proposed measures have not been shown to improve patient outcomes or cost-effectiveness.
It is also unclear how readily primary-care teams could use more detailed neuromuscular assessments. The authors note that specialist expertise is not evenly available. The report does not establish which patients would benefit from specific medication changes or from any treatment aimed at the nervous system, and it provides no trial evidence that the proposed framework reduces falls, disability or deaths.
Validation and Revised Criteria
The authors call for investment in studies that validate practical tests clinicians can use, guidelines that support a staged assessment, and clinical trials that measure nerve function as well as muscle. International working groups that set diagnostic criteria are the intended audience for the paper’s five-point research agenda.
The next evidence needed is whether the broader tests identify relevant causes of weakness more accurately than current screens, and whether acting on those findings improves mobility or other patient outcomes at an acceptable cost. Until that work is done, the motor-system framing remains a research proposal rather than a replacement for current diagnostic practice.
Key Questions
What is sarcopenia?
Sarcopenia refers to substantial loss of muscle, strength and physical function associated with aging. The paper argues that muscle loss alone does not account for all age-related weakness and mobility decline.
What does the motor-system model include?
The authors use “motor system” to describe the parts involved in producing movement, from the brain and spinal cord through nerves and their connections to muscle. They also discuss changes in balance, position sense and movement planning.
Has the proposed approach been shown to prevent falls?
No. The paper proposes tests and research priorities, but the authors say the suggested measures have not been shown to improve outcomes or reduce costs. The report does not establish that the framework prevents falls.
What do the authors suggest clinicians observe?
They suggest considering how quickly a person rises from a chair, steadiness during sustained effort, hand dexterity and walking while talking, alongside established measures such as grip strength and gait speed. These suggestions require further validation and are not presented as proven replacements for current screening.
Source: medicalxpress.com
